Compare drug alternatives
Tafinlar + Mekinist ® Alternatives
Tafinlar + Mekinist ®(Dabrafenib) | Zelboraf®(Vemurafenib) |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | Dosage & Administration comparison data |
Administration | |
Dosing | |
Latin Shorthand | |
| Financial Assistance | Financial Assistance comparison data |
Out-Of-Pocket Costs With Copay Card | |
Annual Cap | |
Assistance Expiration | |
Generics | |
No lower-cost generic available | No lower-cost generic available |
| Physician Advisory | Physician Advisory comparison data |
Adverse Reactions | |
Most common adverse reactions (≥ 20%) for TAFINLAR as a single agent are
hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and
palmar-plantar erythrodysesthesia syndrome.
Most common adverse reactions (≥ 20%) for TAFINLAR in combination with
trametinib include:
• Unresectable or metastatic melanoma: pyrexia, rash, chills, headache,
arthralgia, and cough.
• Adjuvant treatment of melanoma: pyrexia, fatigue, nausea, headache,
rash, chills, diarrhea, vomiting, arthralgia, and myalgia.
• NSCLC: pyrexia, fatigue, nausea, vomiting, diarrhea, dry skin, decreased
appetite, edema, rash, chills, hemorrhage, cough, and dyspnea.
• Adult patients with solid tumors: pyrexia, fatigue, nausea, rash, chills,
headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia,
arthralgia, and edema.
• Pediatric patients with solid tumors: pyrexia, rash, vomiting, fatigue, dry
skin, cough, diarrhea, dermatitis acneiform, headache, abdominal pain,
nausea, hemorrhage, constipation, and paronychia.
• Pediatric patients with LGG: pyrexia, rash, headache, vomiting,
musculoskeletal pain, fatigue, diarrhea, dry skin, nausea, hemorrhage,
abdominal pain, and dermatitis acneiform. . Learn more. | |
Mechanism of Actions (MoA) | |
Special Populations | |
Popular Alternatives
Tafinlar + Mekinist
Other indicationsCompare drug alternatives